South & Central America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country
The South and Central America gastrointestinal drugs market is expected to reach US$ 5,632.72 million by 2027 from US$ 4,160.28 million in 2019; it is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the South & Central America Gastrointestinal Drugs market.
Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.
Gastrointestinal diseases are the conditions that occur in the gastrointestinal tract. Common digestive problems include heartburn, inflammatory bowel diseases (IBD), inflammatory bowel syndrome (IBS), constipation, and diarrhoea. GI diseases account for substantial health care utilization and spending. Growing prevalence of IBD can be ascribed to poor nutritional choices, including a high intake of ultra-processed foods and trans-fats. Several studies have highlighted the accelerated growth of gastrointestinal diseases in South America’s populations during the past two decades. Both incidence and prevalence rates have shown a notable rise, with scientists pointing out that GI diseases are increasingly the cause of morbidity and mortality in American countries. For instance, the most frequently reported diseases in Brazil are gastritis, followed by GERD, hemorrhoids, irritable-bowel syndrome.
Gastrointestinal (GI) diseases, in particular, are becoming common and have been linked to changing environmental factors brought on by improved sanitation, industrialization, changes in diet, and the increased use of antibiotics. Due to these factors, medical device companies in the GI space have been expanding their business operations in South America. The incidence and prevalence of many GI disorders are highest amongst the very young and the elderly. As the population ages, the disease burden is expected to grow. The incidence and prevalence of IBD have increased in the last few decades. Moreover, in the last few years, the cases of IBD have increased. IBD is a chronic inflammation of the digestive tract and is of two types: Ulcerative colitis and Crohn's disease. Thus, the factors mentioned above are driving the adoption of GI drugs during the forecast period.
South and Central America is hit by the COVID-19 pandemic and thus has profound humanitarian, economic, and political consequences. They have responded to the situation by closing borders, ordering quarantines, and imposing a host of restrictions to keep people confined at home. For instance, Brazilian Health Regulatory Agency (ANVISA) has approved RedHill Biopharma Ltd. to conduct clinical trials for its drug for COVID 19. RedHill Biopharma Ltd.is a specialty biopharmaceutical company focusing on gastrointestinal diseases. RedHill is expected to promote the gastrointestinal drugs, Movantik for opioid-induced constipation in adults. Thus, the gastrointestinal drug market is expected to grow in the forecasted period.
Rest of South and Central America Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)
Get more information on this report :
SOUTH AND CENTRAL AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Brazil
- Argentina
- Rest of South and Central America
Company Profiles
- Celltrion Healthcare Co.,Ltd
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South and Central America Gastrointestinal Drugs Market – By Drug Class
1.3.2 South and Central America Gastrointestinal Drugs Market – By Route of Administration
1.3.3 South and Central America Gastrointestinal Drugs Market – By Application
1.3.4 South and Central America Gastrointestinal drugs Market – By Distribution Channel
1.3.5 South and Central America Gastrointestinal drugs Market – By Country
2. South and Central America Gastrointestinal Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South and Central America Gastrointestinal Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Gastrointestinal Drugs Market - South and Central America PEST Analysis
4.3 Expert Opinion
5. South and Central America Gastrointestinal Drugs Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Increase in Development of Biologics
5.2 Market Restraints
5.2.1 Side Effects Associated with The Drugs
5.3 Market Opportunities
5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
5.4 Future Trends
5.4.1 Emergence of Biosimilars
5.5 Impact Analysis
6. Gastrointestinal Drugs Market – South and Central America Analysis
6.1 South and Central America Gastrointestinal Drugs Market Revenue Forecasts and Analysis
7. South and Central America Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class
7.1 Overview
7.2 South and Central America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
7.2.1 South and Central America Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 South and Central America Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Antidiarrheal and Laxatives
7.4.1 Overview
7.4.2 South and Central America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Anti-Inflammatory Drugs
7.5.1 Overview
7.5.2 South and Central America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Antiemetic and Antinauseants
7.6.1 Overview
7.6.2 South and Central America Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Biologics
7.7.1 Overview
7.7.2 South and Central America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
7.8 Others
7.8.1 Overview
7.8.2 South and Central America Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. South and Central America Gastrointestinal Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 South and Central America Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)
8.2.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
8.3 Oral
8.3.1 Overview
8.3.2 South and Central America Oral Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parenteral
8.4.1 Overview
8.4.2 South and Central America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
9. South and Central America Gastrointestinal Drugs Market Analysis – By Application
9.1 Overview
9.2 South and Central America Gastrointestinal Drugs Market, By Application 2019-2027 (%)
9.2.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)
9.3 Inflammatory Ulcerative Colitis
9.3.1 Overview
9.3.2 South and Central America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Crohn's Disease
9.4.1 Overview
9.4.2 South and Central America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Irritable Bowel Syndrome
9.5.1 Overview
9.5.2 South and Central America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Gastroenteritis
9.6.1 Overview
9.6.2 South and Central America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Celiac Disease
9.7.1 Overview
9.7.2 South and Central America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.8 Others
9.8.1 Overview
9.8.2 South and Central America Others Market Revenue and Forecasts to 2027 (US$ Mn)
10. South and Central America Gastrointestinal Drugs Market Analysis – By Distribution Channel
10.1 Overview
10.2 South and Central America Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)
10.2.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
10.3 Hospital Pharmacies
10.3.1 Overview
10.3.2 South and Central America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Retail Pharmacies
10.4.1 Overview
10.4.2 South and Central America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Online Pharmacies
10.5.1 Overview
10.5.2 South and Central America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
11. Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027
11.1.1 Overview
11.1.2 South and Central America: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 South and Central America: Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
11.1.4 South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.5 South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.6 South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.1.7 South and Central America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
11.1.8 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 Brazil: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
11.1.8.3 Brazil: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.8.4 Brazil: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.8.5 Brazil: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.1.9 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 Argentina: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
11.1.9.3 Argentina: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.9.4 Argentina: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.9.5 Argentina: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11.1.10 Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 Rest of South and Central America: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
11.1.10.3 Rest of South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
11.1.10.4 Rest of South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
11.1.10.5 Rest of South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
12. Impact of COVID-19 Pandemic on South and Central America Gastrointestinal Drugs Market
12.1 South and Central America: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Celltrion Healthcare Co.,Ltd.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GlaxoSmithKline plc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 AstraZeneca
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson and Johnson Services, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 Glossary of Terms
LIST OF TABLES
Table 1. South and Central America Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)
Table 2. South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 3. South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 4. South and Central America Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
Table 5. South and Central America: Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 6. South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 7. South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 8. South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. Brazil: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
Table 10. Brazil: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 11. Brazil: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 12. Brazil: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Argentina: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
Table 14. Argentina: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. Argentina: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 16. Argentina: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. Rest of South and Central America: Gastrointestinal Drugs Market, by Therapeutic – Revenue and Forecast to 2027 (USD Million)
Table 18. Rest of South and Central America: Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 19. Rest of South and Central America: Gastrointestinal Drugs Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 20. Rest of South and Central America: Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. Glossary of Terms, Gastrointestinal Drugs Market
LIST OF FIGURES
Figure 1. Gastrointestinal Drugs Market Segmentation
Figure 2. South and Central America Gastrointestinal Drugs Market Overview
Figure 3. Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market
Figure 4. Brazil is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. South and Central America Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)
Figure 6. Gastrointestinal Drugs Market - South and Central America PEST Analysis
Figure 7. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint
Figure 8. South and Central America Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. South and Central America Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
Figure 10. South and Central America Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. South and Central America Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. South and Central America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. South and Central America Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. South and Central America Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. South and Central America Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. South and Central America Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)
Figure 17. South and Central America Oral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. South and Central America Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. South and Central America Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)
Figure 20. South and Central America Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. South and Central America Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. South and Central America Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. South and Central America Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. South and Central America Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. South and Central America Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. South and Central America Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)
Figure 27. South and Central America Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. South and Central America Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. South and Central America Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. South and Central America: Gastrointestinal Drugs Market , by Key Country – Revenue (2019) (USD Million)
Figure 31. South and Central America: Gastrointestinal Drugs Market, Revenue and Forecast to 2027 (USD Million)
Figure 32. South and Central America: Gastrointestinal Drugs Market, by Country, 2019 & 2027 (%)
Figure 33. Brazil: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. Argentina: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. Rest of South and Central America: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in Rest of the World
- Celltrion Healthcare Co.,Ltd
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- It provides understanding of the South and Central America, gastrointestinal drugs market landscape and identifies gastrointestinal drugs market segments that are most likely to guarantee a strong return.
- It guides stay ahead of the race by comprehending the ever-changing competitive landscape for the South and Central America gastrointestinal drugs market.
- It helps efficiently plan merger and acquisition, and partnership deals in the gastrointestinal drugs market by identifying market segments with the most promising probable sales
- It facilitates knowledgeable business decision-making through perceptive and comprehensive analysis of gastrointestinal drugs market performance of various segments pertaining to the South and Central America gastrointestinal drugs market.
- It provides gastrointestinal drugs market revenue forecast of the market based on various segments for the period from 2019 to 2027.